The Complexities of Postpartum Hemorrhage in Antiphospholipid Antibody Syndrome (APLA): A Complex Case Study Analysis

Nanaji A; Naga Phani Sharma; Pavani M; Jaya Radha Madhavi Bonala

A. Nanaji Assistant Professor,Department of Pharmacognacy,Avanthi Institute of Pharmaceutical Sciences
Naga Phani Sharma Assistant Professor,Department of Pharmacy Practice,Avanthi Institute of Pharmaceutical Sciences
M. Pavani Associate professor, Srinivasa rao college of pharmacy
Jaya Radha Madhavi Bonala Avanthi Institute of Pharmaceutical Sciences

Abstract

In the presence of antiphospholipid antibodies, antiphospholipid antibody syndrome (APLA) is an autoimmune thrombophilic condition characterised by recurrent venous, arterial, or small artery thrombosis and pregnancy morbidity. Secondary APS can develop in conjunction with other autoimmune disorders, or it can be primary in the absence of any underlying illness. It's a significant obstetric emergency and one of the leading causes of maternal morbidity and mortality worldwide. Managing postpartum haemorrhage in women with APS can be complex. The use of anticoagulants to manage APS needs to be balanced against the risk of bleeding. Specialists will need to balance the risk of clotting with the risk of bleeding, aiming to provide effective management for both conditions without exacerbating either. This case study elucidates the challenges encountered in the management of postpartum haemorrhage (PPH) associated with Antiphospholipid Antibody Syndrome (APLA). The case of a 24-year-oldpostnatal woman experiencing excessive bleeding following delivery due to APLA and recurrent miscarriages emphasizes the complexities and considerations essential for effective management in such scenarios.

Key words:

Keywords: autoimmune disorder, postpartum haemorrhage, phopholipid-binding proteins

References

1. Antiphospholipid syndrome. Wikipedia, https://en.wikipedia.org/wiki/Antiphospholipid_syndrome (2023).
2. Bustamante JG. Antiphospholipid Syndrome. StatPearls - NCBI Bookshelf, https://www.ncbi.nlm.nih.gov/books/NBK430980/ (2023).
3. Cervera R. Antiphospholipid syndrome. Thromb Res. 2017;151 Suppl1:S43-S47.
4. Kutteh WH, Hinote CD. Antiphospholipid antibody syndrome. ObstetGynecol Clin North Am 2014; 41 (01) 113-132 .
5. Erkan D, Aguiar CL, Andrade D, et al. 14th International Congress on Antiphospholipid Antibodies Task Force. 14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends. Autoimmun Rev. 2014;13(6):685-696.
6. Giannakopoulos B, Krilis SA. The pathogenesis of the antiphospholipid syndrome. N Engl J Med. 2013;368(11):1033-1044.
7. Ruiz-Irastorza G, Crowther M, Branch W, et al. Antiphospholipid syndrome. The Lancet 2010; 376: 1498–1509.